SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a significant analyst upgrade to a $40 price target, fueling speculation about the company's long-term potential as a best-in-class acquisition target for Big Pharma. Investors are closely monitoring upcoming Phase 3 trial data, with the community actively debating whether the company will secure a buyout or continue as an independent entity.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing significant market interest driven by growing anticipation surrounding a potential SpaceX IPO, which investors view as a broader validator for the satellite communications sector. The community is actively debating the company's long-term growth potential and execution roadmap while reacting to recent price volatility and institutional activity.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as retail investors rally behind its long-term potential in AI infrastructure and 6G development, often discussing the stock as a resilient, multi-thematic play despite recent market volatility. Discussion is heavily driven by its strategic partnerships with industry heavyweights like Nvidia, contract wins in defense and optical networking, and persistent institutional accumulation that has fueled bullish sentiment among long-term holders.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

Market sentiment for SPY is currently gripped by extreme volatility and 'extreme fear' as participants debate the potential impact of intensifying conflict in the Middle East, with many traders closely monitoring energy supply disruptions and geopolitical escalations. While the community is sharply divided between those bracing for a deeper correction and those anticipating a potential relief rally, active discussions are focused on how these tensions and shifting macro narratives will influence short-term price action.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo Finance is attracting attention due to its strategic partnership with Franklin Templeton to tokenize traditional assets, fueling investor optimism about its role in bridging Wall Street with decentralized finance. While some in the community remain skeptical of recent price action, many actively discuss its long-term potential as a premier real-world asset (RWA) play.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

ProShares Ultra Bloomberg Crude Oil (UCO) is seeing intense volatility and active retail speculation as the escalating Iran-Middle East conflict threatens global supply lines and the integrity of the Strait of Hormuz. Market participants are intensely debating the tension between supply-side fears of prolonged oil shortages and geopolitical posturing regarding strategic petroleum reserve releases and potential ceasefire negotiations.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is experiencing significant volatility following a critical short-seller report alleging improper revenue recognition and channel stuffing practices. While the company has officially refuted these claims and highlighted its robust growth and buyback program, the community remains divided between investors viewing the sell-off as an extreme buying opportunity and those concerned about the lack of a more comprehensive, point-by-point rebuttal from management.

Invesco CurrencyShares Japanese Yen Trust - Units of fractional undivided beneficial interest

Invesco CurrencyShares Japanese Yen Trust

The Invesco CurrencyShares Japanese Yen Trust is currently a focal point for traders monitoring the global carry trade, with many market participants warning that a strengthening yen could trigger significant volatility across equities and risk assets. The community is closely debating the potential for a larger unwind of yen-funded positions and questioning the currency's historical role as a reliable safe haven amidst shifting macro instability.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently under intense scrutiny as market participants debate its long-term viability, with active discussions focusing on its stability after recent price pullbacks and its role in broader crypto portfolios. While some investors view recent volatility as a strategic accumulation opportunity, others are actively trading based on technical setups, signaling a divergence between long-term holders and momentum traders.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

The DOG community is buzzing following rumors of a Coinbase listing, fueling excitement around its position as a primary memecoin within the Bitcoin Runes ecosystem. Supporters are highlighting its decentralized structure and fixed supply as key advantages over inflationary alternatives, with many actively accumulating in anticipation of a broader market shift.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cybin (NASDAQ:HELP)  Shares Down 2.1%   - Time to Sell?

Cybin (NASDAQ:HELP) Trading Down 2.1% - Here's What Happened...

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions PR Newswire VANCOUVER, BC, March 9, 2026 Issued...

<ul class="summary-bullets"><li>The stock's plunge came after Helus Pharma released results from a mid-stage trial of its anxiety drug HLP004.</li><li>The 36-patient study showed a 10.4-point drop in anxiety scores after six weeks, with 67% of participants responding to treatment.</li><li>Jefferies reiterated a 'Buy' rating and $22 price target, implying a 290% upside from current levels.</li></ul>Shares of Helus Pharma, Inc. (HELP) crashed to their worst trading day on record on Thursday after the company reported results from a mid-stage anxiety drug trial, though Jefferies sees a larger catalyst ahead that could still drive the stock sharply higher.<a href="https://stocktwits.com/symbol/HELP">HELP shares</a> plunged 34% on Thursday to end at $5.64, marking their lowest levels in nearly a year. However, the stock rose over 3% after-hours.&nbsp;<h2 class="st-heading-2">Anxiety Trial Results Trigger Sell-Off</h2>Helus Pharma reported&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/help-stock-tanks-despite-strong-phase-2-results-for-anxiety-treatment-retail-buys-the-dip-ignoring-market-s-pessimism/cZdQHEpRI3O">early results</a> from a mid-stage clinical trial testing HLP004 as a treatment for adults with moderate-to-severe anxiety who continued to have symptoms despite taking antidepressants.The study enrolled 36 patients who received two injections of HLP004 three weeks apart while continuing standard medications. Patients given a 20 mg dose saw anxiety scores drop by about 10.4 points after six weeks. At six months, 67% showed a treatment response and 39% achieved remission.The treatment targets serotonin pathways linked to brain plasticity. In a Phase 1 study using a 30 mg dose, most patients were ready to leave the clinic within about three hours, with the drug’s effects lasting roughly 90 minutes.Generalized anxiety disorder affects more than 20 million adults in the U.S., and roughly half of patients do not respond to first-line treatments, the company said.&nbsp;<h2 class="st-heading-2">Jefferies Bullish On HELP Pipeline</h2>While the anxiety study triggered the sell-off, Jefferies maintained a bullish view on the company’s broader pipeline. The brokerage reiterated a ‘Buy’ rating and a $22 price target on the stock following the data release, implying a 290% upside from current levels.The firm said HLP004 could potentially reduce anxiety symptoms rapidly and durably, and called the generalized anxiety disorder opportunity a $1 billion-plus call option, according to&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.investing.com/news/analyst-ratings/jefferies-reiterates-helus-pharma-stock-rating-on-anxiety-data-93CH-4544705">Investing</a>.&nbsp;However, the brokerage said investors are likely waiting for additional data before gaining greater confidence in the program.&nbsp;Instead, Jefferies highlighted a larger potential catalyst: the Phase 3 Approach trial evaluating Helus Pharma’s lead drug HLP003 for major depressive disorder. HLP003 is an oral drug to treat depression alongside existing medications.&nbsp;Jefferies expects the stock to surge between 100% and 200%, depending on the outcome of the Phase 3 results for HLP003, with results expected in the fourth quarter of 2026.<h2 class="st-heading-2">Depression Trial Pipeline Shows Promise</h2>Last month, results from a mid-stage clinical trial of SPL026 for major depressive disorder were published in the journal Nature Medicine. The randomized study showed a reduction in depressive symptoms within two weeks compared with patients who received a placebo.Researchers also reported that antidepressant effects began appearing as early as one week after treatment, with benefits lasting up to three months in some participants. The findings helped guide the development of Helus Pharma’s newer drug candidates, including HLP004 for anxiety and HLP003 for depression.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for HELP was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/help_ss_png_c6d1ccebbf.webp" alt="help ss.png" width="973" height="141"><figcaption>HELP sentiment and message volume as of March 5 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/macdaddy13333/message/646725489">said</a>, “Correct this is promising info but way too small of a cohort. Big news will be in the phase 3 trials, which can't come out soon enough.”<stembedurl>https://stocktwits.com/macdaddy13333/message/646725489</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Alex1710/message/646759373">said</a>, “This stock will recover, when they knocked at institutionnel doors for cash they answered come in and have a seat.”<stembedurl>https://stocktwits.com/Alex1710/message/646759373</stembedurl>HELP stock has declined 31% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

HELP stock has declined 31% year-to-date. (Photo credit: Getty Images)

HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside

Jefferies highlighted the Phase 3 Approach trial for depression drug HLP003 as the next key catalyst for the stock.

Equity

<ul class="summary-bullets"><li>U.S. stock futures stabilized late Thursday after a sharp sell-off that erased nearly 800 points from the Dow.</li><li>Eight of the 11 S&amp;P 500 sectors closed lower, with industrials, materials, consumer staples, and healthcare each falling at least 2%.</li><li>Asian stocks mostly fell at Friday's open, pulling the broader MSCI Asia Pacific Index down to its steepest weekly decline since 2020.&nbsp;</li></ul>U.S. stock futures steadied late Thursday following a sharp sell-off that wiped nearly 800 points off the Dow, as geopolitical tensions and surging crude prices kept investors on edge.As of 9.20 p.m. ET, Nasdaq 100 and S&amp;P 500 futures were up 0.1%, while Dow futures were up 0.2%.On Stocktwits, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a> was ‘neutral’ amid ‘high’ message volume, while sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> and&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust (DIA)</a> was ‘bearish’ amid ‘high’ message volume.<h2 class="st-heading-2">US Market Drivers</h2>In the prior session, the Dow Jones Industrial Average fell 1.6%. The S&amp;P 500 Index slipped 0.6, while the Nasdaq Composite dipped 0.3%.Eight of the 11 sectors in the S&amp;P 500 closed lower during the session, with industrials, materials, consumer staples, and healthcare each losing at least 2%.Energy markets remained a key driver of volatility. U.S. crude oil prices surged above $80 per barrel during Thursday’s session after Iran reportedly struck an oil tanker with a missile. West Texas Intermediate crude settled up 8.5% at $81.01 per barrel, its highest level since 2024, while Brent crude climbed nearly 5% to around $85.41.The spike in oil prices triggered sharp swings in equity markets. At one point during the session, the Dow fell more than 1,100 points, or about 2.4%, as crude prices crossed the $80 mark before recovering slightly into the close.Oil markets have been shaken by the expanding conflict in the Middle East, which has involved about a dozen countries since hostilities intensified late last month. Traffic through the Strait of Hormuz, a critical route that handles roughly one-fifth of the world’s oil supply, has slowed amid rising security risks.Mohamed El-Erian&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/elerianm/status/2029646631725887998">said on X</a> that the situation involves key market “guardrails” that are currently under stress and warned that if they fail to hold, “the economic and financial dynamics could shift from the more predictable mean reversion to the more uncertain ‘multiple equilibria.’”Meanwhile, investors are also monitoring policy developments in Washington. Treasury Secretary Scott Bessent said the Trump administration’s newly announced 15% global tariff is expected to take effect this week.Despite the broader decline in equities, Berkshire Hathaway stood out as a rare gainer, rising nearly 3% after the company said it has resumed share repurchases for the first time since 2024. CEO Greg Abel also purchased about $15 million worth of company stock.<h2 class="st-heading-2">Trending Stocks To Watch On NYSE, Nasdaq</h2>Indonesia Energy Corp (INDO), Battalion Oil Corp (BATL), United States Oil Fund (USO): INDO rose over 1% in extended trading, while BATL jumped nearly 16%, as oil prices headed for their&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/indo-batl-uso-in-focus-oil-rally-middle-east-war-1b-fuel-bill/cZdhSDMRIEc">biggest weekly gain</a> since 2022. USO climbed to its highest level in six years.Marvell Technology (MRVL): Shares surged about 15% after-hours as the company issued first-quarter fiscal 2027&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mrvl-shares-surge-on-solid-q1-2027-guidance/cZdX3fORI3x">revenue guidance</a> above Wall Street estimates and projected full-year revenue growth of more than 30%.Costco Wholesale (COST): Shares slipped slightly in extended trading despite the warehouse retailer reporting&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/costco-q2-sales-growth-trails-wall-street-expectations/cZdX3ouRI3U">second-quarter earnings</a> and revenue that topped analyst estimates.Helus Pharma (HELP): Shares plunged 34% in Thursday’s session, marking their worst trading day on record, after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/help-stock-tanks-despite-strong-phase-2-results-for-anxiety-treatment-retail-buys-the-dip-ignoring-market-s-pessimism/cZdQHEpRI3O">Phase 2 results</a> for its anxiety treatment HLP004 disappointed investors.Newsmax (NMAX): Shares headed for their&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/newsmax-stock-heads-for-best-week-since-ipo/cZdhkXqRIE2">best weekly performance</a> since the company’s IPO following strong viewership numbers tied to its coverage of President Donald Trump’s State of the Union address.<h2 class="st-heading-2">How Global Markets Are Performing Today</h2>In broader markets, the yield on the benchmark 10-year U.S. Treasury note was around 4.14%, while gold traded near $5,093 an ounce in early Asian trading. Silver was near $82.47, while platinum and palladium also moved higher.Asian markets were lower on Friday, with stocks in Japan, South Korea and Australia falling at the open, pulling the broader MSCI Asia Pacific Index down about 0.6%. The index has dropped roughly 6.7% since the war began, marking its steepest weekly decline since 2020.Among the catalysts for the day are the U.S. employment report, retail sales data, business inventories and consumer credit figures, along with remarks from Federal Reserve officials Mary Daly and Beth Hammack.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Dow Jones Industrial Average closes above the 50,000 mark for the first time ever, seen in this photo illustration in Brussels, Belgium, on February 7, 2026. (Photo Illustration by Jonathan Raa/NurPhoto via Getty Images)

Dow Futures Hold Ground After 800-Point Selloff As Oil Surge Hits Wall Street: Why MRVL, USO, COST, HELP Are Trending After-Hours

U.S. crude surged above $80 per barrel after a reported Iranian missile strike on an oil tanker.

Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints

Helus Pharma (Cybin) shares fall after Phase 2 anxiety drug results show symptom improvement, but pressure on the stock.read more...

Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion

Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion PR Newswire NEW YORK, March 5, 2026 GAD...

FY2026 Earnings Forecast for Cybin Issued By HC Wainwright

Cybin Inc. (NASDAQ:HELP - Free Report) - Analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Cybin in a research note issued to investors on Monday, March 2nd...

<ul class="summary-bullets"><li>The clinical trial included 36 participants who continued taking existing medications for generalized anxiety disorder while receiving HLP004 injections.</li><li>Researchers administered two doses three weeks apart and monitored participants for 12 weeks.</li><li>Six months after treatment, about 67% of the combined study group met the criteria for a clinical response.</li></ul>Helus Pharma (HELP) announced encouraging early-stage clinical results for its experimental anxiety treatment HLP004 on Thursday, reporting notable symptom improvement among patients with moderate-to-severe generalized anxiety disorder.&nbsp;The clinical-stage drug developer said its Phase 2 signal detection trial showed statistically meaningful improvements when the therapy was used alongside standard antidepressant treatments.&nbsp;<h2 class="st-heading-2">Trial Demonstrates Significant Anxiety Reduction</h2>In the study, participants receiving a 20-milligram dose of HLP004 alongside standard-of-care treatment experienced an average drop of roughly 10.4 points on the Hamilton Anxiety Rating Scale after six weeks.&nbsp;The clinical trial included 36 participants who continued taking existing medications for generalized anxiety disorder while receiving HLP004 injections. Researchers administered two doses, three weeks apart, and monitored participants for 12 weeks, with additional follow-up planned for up to 1 year.<a href="https://stocktwits.com/symbol/HELP">Helus Pharma stock</a> traded over 22% lower in Thursday’s remarket.&nbsp;<h2 class="st-heading-2">Long-Lasting Response Observed In Many Patients</h2>The company also reported sustained benefits beyond the initial treatment period. Six months after treatment, about 67% of the combined study group met the criteria for a clinical response, while 39% reached remission.Among those receiving the higher 20-milligram dose, 59% showed improvement and 32% achieved remission after six weeks. In the lower-dose group, about 30% of patients met response and remission benchmarks at the same time point.<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2>Despite the stock’s decline in the premarket session, retail sentiment on Stocktwits around the stock flipped to ‘extremely bullish’ from ‘neutral’ territory the previous day. Message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_05_083359_png_25a9744605.webp" alt="HELP’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Mar. 5, 2026 | Source: Stocktwits" width="925" height="96"><figcaption>HELP’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Mar. 5, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user said they have bought the dip.&nbsp;<stembedurl>https://stocktwits.com/Jimbob3016/message/646658779</stembedurl>HELP stock has gained over 4% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/liquidia-stock-gains-premarket-on-q4-revenue-beat-investors-are-betting-on-yutrepia-growth/cZdQrwNRI33">Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism

In the study, participants receiving a 20-milligram dose of HLP004 alongside standard-of-care treatment experienced an average drop of roughly 10.4 points on the Hamilton Anxiety Rating Scale after six weeks. 

Cybin (NASDAQ:HELP) Price Target Raised to $95.00 at HC Wainwright

HC Wainwright boosted their price target on Cybin from $55.00 to $95.00 and gave the company a "buy" rating in a report on Monday...

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments PR Newswire VANCOUVER, BC, Feb. 27...

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

Current Price	$4.52
Prev Close	$4.65
Open	$4.65
Dividend Yield	N/A
50-Day Moving Average	$6.33
Beta	0.98
Avg. Volume	639,409.13
PE Ratio	-1.00

52-Week High	$9.83
52-Week Low	$4.41
Market Capitalization	$226.16M
EPS (Annual)	-$4.02
Price to Book	0.82
Revenue Per Employee	$0.00

HELP
Helus Pharma Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HELP News

HELPHelus Pharma Inc.